COLLEGIUM PHARMACEUTICAL, INC (COLL): Termination of a Material Definitive Agreement

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which

Original reporting
Published Oct 19, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$COLL
Bullish
high confidence
Mentioned
$COLL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COLLBullishMed
01

Why it matters

The settlement ends royalty payments and may enhance profitability, but requires a $17 M cash payment.

02

Market read

A primary corporate action disclosure that could affect COLL's share price through improved cash flow outlook.

03

What to watch

Potential future litigation risk if the settlement does not fully resolve patent disputes.

Relevance 6/10Novelty 8/10Timing: post-settlement (effective Oct 15 2026, disclosed Oct 19 2026)

Background

COLL filed an 8‑K reporting termination of a material license agreement with Grünenthal and a settlement of related patent litigation.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

COLL settled a $17 million dispute with Grünenthal, terminating the license and ending royalty obligations, which could improve cash flow and earnings outlook.

Expected impact

likely upward pressure as investors price in royalty relief and reduced expense

Evidence & confidence

The $17 M payment eliminates future royalty payments; market typically rewards removal of ongoing obligations.

Market effects

May improve outlook for other companies with similar royalty structures in the pain‑management space.

Limited to U.S. biotech/pharma sector.

Minimal; primarily a company‑specific event.

Counterpoint

The $17 M cash outflow could strain short‑term liquidity, offsetting royalty savings.

Key entities

  • Collegium Pharmaceutical, Inc.

    Issuer of the 8‑K, subject of the settlement.

  • Grünenthal GmbH

    Counterparty in the license and litigation.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.